Please login to the form below
Novimmune
This page shows the latest Novimmune news and features for those working in and with pharma, biotech and healthcare.
Sobi’s Gamifant receives final rejection from CHMP for primary HLH
Sobi, based in Stockholm, Sweden, acquired the global marketing rights to Gamifant from Novimmune in July 2018, and in June 2019 the company spent $518m to acquire the outstanding intellectual property
Latest news
-
AstraZeneca buys FDA priority review voucher from Sobi
Sobi gained the PRV during the acquisition of Novimmune’s Gamifant (emapalumab) related business earlier this year.
-
Sobi takes ownership of rare disease drug Gamifant for $518m
Gamifant (emapalumab) was developed by Swiss specialist pharma company Novimmune and gained FDA approval in November 2018. ... companies. Novimmune submitted emapalumab to the European Medicines Agency in November last year, with a decision from the CHMP
-
Sobi shows strong growth despite haemophilia competition
The ultra-rare disease therapy was licensed from Novimmune for $452m last year, and gives Sobi an expanded presence in the all important US market.
-
Orphan drugs dominate FDA's record-breaking year
myasthenic syndrome (LEMS), Novimmune’s Gamifant (emapalumab) for primary hemophagocytic lymphohistiocytosis (HLH), Regeneron/Sanofi’s Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC), and SIGA Technologies’ TPOXX (tecovirimat)
-
FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease
Approval adds to growing US portfolio. Swedish Orphan Biovitrum (Sobi) has the US approval it sought for Gamifant, an ultra-rare disease therapy it licensed from Novimmune for $452m a few ... The Swedish company took a global license to the drug from
More from news
Approximately 1 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Sosei appoints CFO
Prior to this, he held the same title at several other biotech companies, including Actelion and Novimmune.
-
Novimmune appoints Guillaume de Sampaïo
Prior to joining Novimmune he served at Danish biotech firm Forward Pharma, where he created and managed its clinical development group. ... Guillaume de Sampaïo will help us to further advance Novimmune as we move closer to the market with our lead
-
Novimmune expands senior management team
Fleurant joins Novimmune with 20 years of quality expertise in life sciences, most recently having served as head of quality affairs at Alvotech, an Icelandic biosimilars specialist. ... Eduard Holdener, chairman and chief executive of Novimmune, said:
More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- World AIDS Day 35: Medscape’s Commitment to the Elimination of HIV through Education and Looking Towards the Future
- No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards
- Building trust with HCPs: 6 takeaways from our industry webinar
- Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m
- NHS to offer stem cell transplants to patients living with rare blood disorder
- First WHO Global Clinical Trial Forum develops joint vision to improve clinical research
No results were found
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
